Summit Therapeutics PLC (SMMT)
| Market Cap | 641.33M |
| Revenue (ttm) | 728,000 |
| Net Income (ttm) | n/a |
| Shares Out | 97.24M |
| EPS (ttm) | -0.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 24 |
| Last Price | $6.46 |
| Previous Close | $6.47 |
| Change ($) | -0.01 |
| Change (%) | -0.15% |
| Day's Open | 6.69 |
| Day's Range | 6.40 - 6.71 |
| Day's Volume | 204,151 |
| 52-Week Range | 3.14 - 12.30 |
Cambridge, MA, June 08, 2021 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) is set to join the broad-market Russell 3000® Index at the conclusion of the 2021 Russell indexes annual reconsti...
Summit Therapeutics PLC (SMMT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...
Shares of Summit Therapeutics Inc. (NASDAQ:SMMT) stock had a big move higher Monday. After reporting earnings and giving a clinical trial update, the stock gained $1.44 a share, a move of almost 27%.
Summit Therapeutics Inc (NASDAQ: SMMT) has selected a new preclinical candidate, SMT026738 (SMT-738), for development against multidrug-resistant infections, specifically carbapenem-resistant Enterobact...
Find out why investors are more excited than ever about these two businesses.
Cambridge, MA, May 17, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today reports its financial results and provides an update on its operational progress for the first quarter ended March 31, 2021.
Cambridge, MA, May 12, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) announced today the successful closing of its fully subscribed rights offering and the associated results.
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that we have updated the scientific and related content on our corporate website with respect to our investigational ...
Cambridge, MA, May 5, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it is nearing the previously-announced expiration date for its rights offering of 5:00 pm Eastern Daylight Time ...
Summit Therapeutics Inc. (‘Summit' or the ‘Company')
Cambridge, MA, March 26, 2021 - Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that the Company's Board of Directors has approved a rights offering available to all holders of record of the Com...
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Summit Therapeutics Inc. (‘Summit,' the ‘Company,' or the ‘Group')
Summit Therapeutics Inc. (‘Summit', the ‘Company' or the ‘Group')
Summit Therapeutics Inc. (“Summit” or the “Company”)
Summit Therapeutics Inc.
Summit Therapeutics Inc. (‘Summit’, the ‘Company’ or the ‘Group’)
Summit Therapeutics plc
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.75, marking a +1.08% move from the previous day.
Summit Therapeutics plc (‘Summit’, the ‘Company’ or the ‘Group’)
Is (SMMT) Outperforming Other Medical Stocks This Year?
In the latest trading session, Summit Therapeutics PLC (SMMT) closed at $3.48, marking a -0.43% move from the previous day.
Is (SMMT) Outperforming Other Medical Stocks This Year?
Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.11, moving +0.33% from the previous trading session.
Summit Therapeutics PLC (SMMT) closed the most recent trading day at $3.68, moving +0.55% from the previous trading session.
Summit Therapeutics (SMMT) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Does Summit Therapeutics PLC (SMMT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Coronavirus shows signs of slowdown in the United States and some other countries. While investors look for positive developments in the stock market, here are five must-buy stocks poised to grow.
Top Ranked Momentum Stocks to Buy for April 7th
Top Ranked Momentum Stocks to Buy for March 26th
Top Ranked Momentum Stocks to Buy for March 25th
Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)
Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
TR-1: S tandard form for notification of major holdings
Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)
Summit Therapeutics plc (‘Summit’ or the ‘Company’)
Summit Therapeutics plc (‘Summit’ or the ’Company’)
Summit Therapeutics plc (“Summit Therapeutics” or the “Company”)
About SMMT
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva pl... [Read more...]
| Industry Biotechnology | Founded 2003 |
| Stock Exchange NASDAQ | Ticker Symbol SMMT |
Analyst Forecasts
The average 12-month stock price forecast for SMMT is 4.50, which is a decrease of -30.34% from the latest price.